The duration of treatment depends on your individual goals and how your body responds
clinical complexity slows uptake Long-acting or micro-dosages (e.g., monthly injections, microneedle patches) What changes: Improved tolerability, better adherence Where it moves : Possibly back toward DTC models if access outpaces infra Strategic shift: Less patient burden, potential wedge for intermediaries Risk: Manufacturing lag or cost may stall rollout
Having a reduced appetite can lower the number of calories you consume
For those who have tried other clinics and were unsuccessful, we can find a solution
Avoiding the rebound, therefore, lies in the GLP-1 patients ability to embrace healthier eating while on the drugs and then sustaining these new habits when they finish taking them, explains UK dietician and nutritionist, Dr Sarah Schenker